Navigation Links
Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain
Date:12/9/2009

the scale used in the 702 and 703 studies. The Company will use the top-line data, expected in May 2010, from the Daisy PETAL Study to inform our Phase 3 protocol design which it intends to submit as a Special Protocol Assessment to the FDA.

Conference Call and Webcast Information

The Company will host a live conference call and webcast to provide additional details of this study today at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time). Participants can access the live conference call by dialing 1-800-862-9098(US) or 785-424-1051(International) using the conference ID: 7GNRH1. The call can also be accessed via the webcast through the Company's website at http://www.neurocrine.com.

If you are unable to attend the Webcast and would like further information on this announcement please contact the Investor Relations Department at Neurocrine Biosciences at (858) 617-7600. A replay of the Conference Call will be available approximately one hour after the conclusion of the call by dialing 1-800-688-7339(US) or 402-220-1347(International) using the conference ID: 7GNRH1. The call will be archived for two weeks.

Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on neurological and endocrine diseases and disorders. Our product candidates address some of the largest pharmaceutical markets in the world including endometriosis, anxiety, depression, pain, diabetes, benign prostatic hyperplasia (BPH), irritable bowel syndrome (IBS) and other neurological and endocrine related diseases and disorders. Neurocrine Biosciences, Inc. news releases are available through the Company's website via the internet at http://www.neurocrine.com

In addition to historical facts, this press release may contain forward-looking statements that involve a number of risks and uncertainties. A
'/>"/>

SOURCE Neurocrine Biosciences, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Neurocrine Biosciences Amends Corporate Headquarters Lease
2. Neurocrine Biosciences to Present at the UBS Global Life Sciences Conference
3. Neurocrine Biosciences Secures Committed Equity Financing Facility
4. Neurocrine Biosciences Reports Second Quarter 2009 Results
5. Webcast Alert: Neurocrine Biosciences Announces 2nd Quarter 2009 Earnings Results
6. Neurocrine Biosciences Announces Conference Call and Webcast to Present Second Quarter 2009 Financial Results
7. Neurocrine Biosciences to Present at the 8th Annual Needham Life Sciences Conference
8. Neurocrine Biosciences to Present at the Deutsche Bank 34th Annual Health Care Conference
9. Neurocrine Biosciences Reports First Quarter 2009 Results
10. Neurocrine Announces Work Force Restructuring
11. Neurocrine Biosciences to Present at the 16th Annual Future Leaders in the Biotech Industry Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... is the device," Nobel laureate Herbert Kroemer famously ... found at the junctures where layers of different ... the interfaces between layers of metal oxides are ... favorites as spintronics, high-temperature superconductors, ferroelectrics and multiferroics. ...
(Date:1/15/2014)... Look inside the new Preferred Solutions® catalog ... from fluid handling to instruments to supplies. Many items ... order. , Preferred Solutions features a full selection ... model for precise flow control and dispensing to I/P® ...
(Date:1/15/2014)... This webinar will focus on EMA and ... in biosimilars. , Regulatory frameworks are evolving many countries ... the complex nature of biopharmaceuticals makes the demonstration of ... challenging. Based on the specific aspects of biosimilar drug ...
(Date:1/15/2014)... Rochester, NY (PRWEB) January 15, 2014 The ... cause a major disease. One of these latent viruses is ... is rheumatoid arthritis (RA). Rheumatoid arthritis (RA) is a chronic ... the theory, a study found that RA patients have high ...
Breaking Biology Technology:A deeper look at interfaces 2Cole-Parmer Begins 2014 with the Release of Preferred Solutions 2Xtalks Life Sciences Webinar Examines Safety Assessment of Biosimilars 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 3
... , KALAMAZOO, Mich., Nov. 3 Tolera Therapeutics, Inc., ... application with the United States Food and Drug Administration ... acute rejection of solid organ transplantation. TOL101 is ... and specifically target T cells, components of the immune ...
... , SOUTH SAN FRANCISCO, Calif., Nov. 3 Poniard Pharmaceuticals, ... oncology, today reported financial results for the third quarter ended ... "During the third quarter, we reached the 320th event target ... picoplatin for the treatment of small cell lung cancer. ...
... November 3 The new market research,report, ,Global ... 2014),published by MarketsandMarkets ( http://www.marketsandmarkets.com ) analyzes,the major ... identifies and analyzes,the main market drivers, restraints, and ... submarkets in different,geographic regions. , ...
Cached Biology Technology:Tolera Therapeutics Files IND Application for TOL101, Appoints O'Toole to Lead Clinical Operations 2Poniard Pharmaceuticals Reports Third Quarter 2009 Financial Results and Provides a Corporate Update 2Poniard Pharmaceuticals Reports Third Quarter 2009 Financial Results and Provides a Corporate Update 3Poniard Pharmaceuticals Reports Third Quarter 2009 Financial Results and Provides a Corporate Update 4Poniard Pharmaceuticals Reports Third Quarter 2009 Financial Results and Provides a Corporate Update 5Poniard Pharmaceuticals Reports Third Quarter 2009 Financial Results and Provides a Corporate Update 6Poniard Pharmaceuticals Reports Third Quarter 2009 Financial Results and Provides a Corporate Update 7MarketsandMarkets: Global Stem Cell and Advanced Technologies Market Worth US$ 88.3 Billion By 2014 2MarketsandMarkets: Global Stem Cell and Advanced Technologies Market Worth US$ 88.3 Billion By 2014 3
(Date:4/23/2014)... transformed the energy landscape in the U.S., but ... among the energy industry, residents and agricultural interests ... that degraded water quality is a potential risk ... appears in the ACS journal Environmental Science ... colleagues point out that a major criticism of ...
(Date:4/23/2014)... from using triclosan as an antimicrobial ingredient in soaps, ... scientists are reporting new evidence that appears to support ... Chemical Research in Toxicology , found that triclosan, ... the growth of human breast cancer cells in lab ... Choi and colleagues note that hormonal imbalances seem to ...
(Date:4/23/2014)... today announced Sophie Martin of the University of Lausanne, ... Medal. The award acknowledges her work to understand the ... the cell. , Martin has been working for the ... the way in which the spatial organization of cells ... last 11 years, she has been using fission yeast, ...
Breaking Biology News(10 mins):How to avoid water wars between 'fracking' industry and residents 2In lab tests, the antimicrobial ingredient triclosan spurs growth of breast cancer cells 2EMBO Gold Medal 2014 awarded to Sophie Martin 2
... block CNS infectionA single molecular anchor that allows bacteria to ... many types of bacterial meningitis, a University of California, San ... By blocking the molecule's anchoring ability, researchers may be able ... serious infection of the central nervous system and a major ...
... cruel disease. Left untreated, prostate cancer cells often metastasize, ... that are extremely painful. , More than 80 ... with metastatic disease in their bones. But scientists know ... up housekeeping in bone tissue and produce the dense ...
... this webpage for pictures and videos! , With ... sea lilies look a lot like their garden-variety namesakes. Perhaps ... lilies stayed rooted instead of moving around like their stalkless ... a submersible research vessel at a depth of 430 meters ...
Cached Biology News:Researchers identify molecular anchor that allows bacterial invasion of central nervous system 2Researchers identify molecular anchor that allows bacterial invasion of central nervous system 3Prostate cancer uses Wnt signaling proteins to promote growth of bone tumors 2Prostate cancer uses Wnt signaling proteins to promote growth of bone tumors 3U. of Colorado researcher identifies tracks of swimming dinosaur in Wyoming 2U. of Colorado researcher identifies tracks of swimming dinosaur in Wyoming 3
human Exodus-2 Research Focus: cytokine/growth factor Storage Temperature: -20C Shipping Temperature: 4C...
MAb to IgG2 (Fc gamma-2) IgG2 (Fc, gamma-2 epitope)...
... formulated for non-denaturing polyacrylamide and agarose gel ... solution contains a bromophenol blue tracking dye ... sample loading. EDTA has been included to ... SDS has been added to help dissociate ...
... Polyclonal Antibody Description: ... polyclonal antibody. Detects 70 kDa YAP ... blotting and immunohistochemistry. ... Storage: -20C ...
Biology Products: